Literature DB >> 16799481

Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma.

Véronique Winnepenninckx1, Maria Debiec-Rychter, Jeroen A M Beliën, Pierre Fiten, Stefan Michiels, Vladimir Lazar, Ghislain Opdenakker, Gerrit A Meijer, Alain Spatz, Joost J van den Oord.   

Abstract

Human pituitary tumour-transforming gene 1 or hPTTG1 is a proto-oncogene that codes for securin, a protein involved in sister chromatid separation. Based on previous microarray data, we studied the expression of hPTTG1/securin in melanocytic lesions. In contrast to nevi and radial growth phase melanomas, securin was expressed by scattered cells in the vertical growth phase, suggesting a role in tumour progression. In a series of 29 nodular and 29 superficial spreading melanomas, matched for all histological prognostic parameters, securin expression was significantly correlated with the nodular subtype (P=0.018) and not related to thickness. In other cancers, hPTTG1 is involved in various oncogenic pathways, including induction of neovascularisation and aneuploidy, and inhibition of p53 activity. We found coexpression of securin with wild-type p53 in the same neoplastic cells in a minority of melanomas. Expression of securin was significantly correlated with the extent of aneuploidy but not with basic fibroblast growth factor immunoreactivity or microvessel density. DNA cytometry revealed that nuclei-overexpressing securin frequently showed tetraploidy or aneuploidy. Our data show that hPTTG1 is frequently overexpressed in nodular melanoma, and suggest that hPTTG1 may act as an oncogene in the vertical growth phase, either by inhibiting anaphase, thereby causing aneuploidy and genomic instability, or by modulating the function of p53, thereby impairing apoptosis. Published online 23 June 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799481     DOI: 10.1038/modpathol.3800627

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  9 in total

Review 1.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

2.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

3.  CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.

Authors:  Lisa Zhang; Reza Rahbari; Mei He; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2011-11-28       Impact factor: 5.678

4.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years.

Authors:  Melanie A Warycha; Paul J Christos; Madhu Mazumdar; Farbod Darvishian; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Alfred W Kopf; David Polsky; Iman Osman
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

6.  New Perspectives of "omics" Applications in Melanoma Research.

Authors:  Carmen Rodríguez-Cerdeira; Alberto Molares-Vila
Journal:  Open Biochem J       Date:  2011-12-30

Review 7.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

8.  PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.

Authors:  Jacqueline E Noll; Kate Vandyke; Duncan R Hewett; Krzysztof M Mrozik; Rachel J Bala; Sharon A Williams; Chung H Kok; Andrew Cw Zannettino
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

9.  Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.

Authors:  Simona Caporali; Ester Alvino; Pedro Miguel Lacal; Federica Ruffini; Lauretta Levati; Laura Bonmassar; Alessandro Scoppola; Paolo Marchetti; Simona Mastroeni; Gian Carlo Antonini Cappellini; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-12-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.